TY  - JOUR
AU  - Maghfour, Jalal
AU  - Sivesind, Torunn Elise
AU  - Dellavalle, Robert Paul
AU  - Dunnick, Cory
PY  - 2021
DA  - 2021/10/1
TI  - Trends in Hidradenitis Suppurativa Disease Severity and Quality of Life Outcome Measures: Scoping Review
JO  - JMIR Dermatol
SP  - e27869
VL  - 4
IS  - 2
KW  - hidradenitis suppurativa
KW  - severity of illness index
KW  - patient-reported outcome measures
KW  - quality of life
KW  - treatment outcome
KW  - illness index
KW  - patient outcomes
KW  - disease severity
KW  - Sartorius
KW  - dermatology
KW  - treatment interventions
AB  - Background: Although there has been an increase in the number of randomized controlled trials evaluating treatment efficacy for hidradenitis suppurativa (HS), instrument measurements of disease severity and quality of life (QoL) are varied, making the compilation of data and comparisons between studies a challenge for clinicians. Objective: We aimed to perform a systematic literature search to examine the recent trends in the use of disease severity and QoL outcome instruments in randomized controlled trials that have been conducted on patients with HS. Methods: A scoping review was conducted in February 2021. The PubMed, Embase, Web of Science, and Cochrane databases were used to identify all articles published from January 1964 to February 2021. In total, 41 articles were included in this systematic review. Results: The HS Clinical Response (HiSCR) score (18/41, 44%) was the most commonly used instrument for disease severity, followed by the Sartorius and Modified Sartorius scales (combined: 16/41, 39%). The Dermatology Life Quality Index (18/41, 44%) and visual analogue pain scales (12/41, 29%) were the most commonly used QoL outcome instruments in HS research. Conclusions: Randomized controlled trials conducted from 2013 onward commonly used the validated HiSCR score, while older studies were more heterogeneous and less likely to use a validated scale. A few (6/18, 33%) QoL measures were validated instruments but were not specific to HS; therefore, they may not be representative of all factors that impact patients with HS. Trial Registration: National Institute of Health Research PROSPERO CRD42020209582; https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020209582 
SN  - 2562-0959
UR  - https://derma.jmir.org/2021/2/e27869
UR  - https://doi.org/10.2196/27869
UR  - http://www.ncbi.nlm.nih.gov/pubmed/37632807
DO  - 10.2196/27869
ID  - info:doi/10.2196/27869
ER  -